Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 0.2% - What's Next?

Key Points

• Greenwich LifeSciences' shares experienced a slight decline of 0.2%, trading between $9.76 and $10.40, with trading volume increasing by 28% compared to the average.
• The company received an "outperform" rating and a price target of $45.00 from Noble Financial, contributing to a consensus "Buy" rating with an average target price of $42.00.
• Greenwich LifeSciences reported a quarterly earnings per share of ($0.30), missing the estimate by $0.06, with expectations of posting -0.8 EPS for the current year.

Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) were down 0.2% on Friday . The stock traded as low as $9.76 and last traded at $10.40. Approximately 104,248 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 81,460 shares. The stock had previously closed at $10.42.

Analyst Ratings Changes

Separately, Noble Financial started coverage on Greenwich LifeSciences in a research note on Wednesday, August 20th. They issued an "outperform" rating and a $45.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Greenwich LifeSciences presently has a consensus rating of "Buy" and a consensus price target of $42.00.

Greenwich LifeSciences Price Performance

The company has a market capitalization of $141.75 million, a PE ratio of -7.65 and a beta of 1.66. The company has a 50 day moving average of $11.52 and a two-hundred day moving average of $10.45.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). On average, equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current year.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in shares of Greenwich LifeSciences by 1.4% in the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company's stock worth $1,261,000 after acquiring an additional 1,972 shares during the last quarter. Northern Trust Corp grew its stake in shares of Greenwich LifeSciences by 17.3% in the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company's stock worth $982,000 after acquiring an additional 12,923 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Greenwich LifeSciences in the second quarter worth $509,000. Charles Schwab Investment Management Inc. grew its stake in shares of Greenwich LifeSciences by 15.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company's stock worth $181,000 after acquiring an additional 2,552 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Greenwich LifeSciences in the first quarter worth $177,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.